Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
3.050
+0.040 (1.33%)
At close: Sep 25, 2026, 4:00 PM EDT
3.010
-0.040 (-1.31%)
After-hours: Sep 25, 2026, 7:30 PM EDT
Niagen Bioscience Revenue
Niagen Bioscience had revenue of $29.79M in the quarter ending June 30, 2026, a decrease of -4.28%. This brings the company's revenue in the last twelve months to $129.08M, up 10.99% year-over-year. In the year 2025, Niagen Bioscience had annual revenue of $129.42M with 29.95% growth.
Revenue (ttm)
$129.08M
Revenue Growth
+10.99%
P/S Ratio
1.87
Revenue / Employee
$1,103,282
Employees
117
Market Cap
241.84M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 129.42M | 29.83M | 29.95% |
| Dec 31, 2024 | 99.60M | 16.03M | 19.18% |
| Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
| Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
| Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
| Dec 31, 2020 | 59.26M | 12.97M | 28.01% |
| Dec 31, 2019 | 46.29M | 14.73M | 46.69% |
| Dec 31, 2018 | 31.56M | 10.36M | 48.85% |
| Dec 30, 2017 | 21.20M | -463.65K | -2.14% |
| Dec 31, 2016 | 21.66M | 3.78M | 21.13% |
| Jan 2, 2016 | 17.88M | 2.57M | 16.79% |
| Jan 3, 2015 | 15.31M | 5.15M | 50.71% |
| Dec 28, 2013 | 10.16M | -1.45M | -12.48% |
| Dec 29, 2012 | 11.61M | 3.50M | 43.12% |
| Dec 31, 2011 | 8.11M | 546.24K | 7.22% |
| Jan 1, 2011 | 7.57M | 1.79M | 30.95% |
| Jan 2, 2010 | 5.78M | 1.27M | 28.22% |
| Jan 3, 2009 | 4.51M | -247.77K | -5.21% |
| Dec 29, 2007 | 4.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| B&G Foods | 1.77B |
| Oatly Group AB | 925.00M |
| USANA Health Sciences | 913.36M |
| Nature's Sunshine Products | 492.02M |
| BRC Inc. | 429.70M |
| Beyond Meat | 258.85M |
| Lifeway Foods | 242.41M |
| Mama's Creations | 208.60M |
NAGE News
- 5 days ago - Niagen Bioscience announces publication of preclinical study on CD38 - TheFly
- 5 days ago - Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes - Business Wire
- 9 days ago - Niagen Bioscience subsidiary engaged Red Sky Partners to support NB4168 - TheFly
- 9 days ago - Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth - Business Wire
- 16 days ago - Niagen Bioscience to Present at Canaccord Genuity's Well Summit - Business Wire
- 24 days ago - Niagen Bioscience to Present at Longevity Investors Conference - Business Wire
- 4 weeks ago - Niagen Bioscience Transcript: 17th Annual Midwest IDEAS Conference - Transcripts
- 4 weeks ago - Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit - Business Wire